MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

References

• Jeyalakshmi K, Kumar S, Amber K, et al. Computational analysis of miRNA and their gene targets significantly involved in colorectal cancer progression. MicroRNA. 2018;7:1–9.
   Google Scholar
• Zhang J, Dhakal IB, Zhao Z, et al. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev. 2012;21:480–489.
   PubMed Web of Science ®Google Scholar
• Rasmussen MH, Lyskjaer I, Jersie-Christensen RR, et al. miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nat Commun. 2016;7:12436.
   PubMed Web of Science ®Google Scholar
• Rasmussen MH, Jensen NF, Tarpgaard LS, et al. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637–646.
   PubMed Web of Science ®Google Scholar
• Graham J, Muhsin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004;3:11.
   PubMed Web of Science ®Google Scholar
• Hector S, Bolanowska-Higdon W, Zdanowicz J, et al. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol. 2001;48:398–406.
   PubMed Web of Science ®Google Scholar
• Landriscina M, Maddalena F, Laudiero G, et al. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal. 2009;11:2701–2716.
   PubMed Web of Science ®Google Scholar
• Ahmad S. Platinum–DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers. 2010;7:543–566.
   PubMed Web of Science ®Google Scholar
• Yang SY, Sales KM, Fuller B, et al. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med. 2009;15:225–233.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Tozzi F, Chen J, et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 2012;72:304–314.
   PubMed Web of Science ®Google Scholar
• Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132:9–14.
   PubMed Web of Science ®Google Scholar
• Lu R, Ji Z, Li X, et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014;140:387–397.
   PubMed Web of Science ®Google Scholar
• Xu W-G, Shang Y-L, Cong X-R, et al. MicroRNA-135b promotes proliferation, invasion and migration of osteosarcoma cells by degrading myocardin. Int J Oncol. 2014;45:2024–2032.
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–433.
   PubMed Web of Science ®Google Scholar
• Kurokawa K, Tanahashi T, Iima T, et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012;47:883–895.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wan G, Spizzo R, et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 2014;8:83–92.
   PubMed Web of Science ®Google Scholar
• Pepe F, Pagotto S, Soliman S, et al. Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis. 2017;6:e328.
   PubMed Web of Science ®Google Scholar
• Arrighetti N, Cossa G, De Cecco L, et al. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol. 2016;310:9–19.
   PubMed Web of Science ®Google Scholar
• Bertero T, Bourget-Ponzio I, Puissant A, et al. Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle. 2013;12:2183–2193.
   PubMed Web of Science ®Google Scholar
• Wen S, Wang X, Wang Y, et al. Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(Suppl. 1):896–905.
   Web of Science ®Google Scholar
• Xu Y, Zhang C, Liang H, et al. Dishevelled 1, a pivotal positive regulator of the Wnt signalling pathway, mediates 5-fluorouracil resistance in HepG2 cells. Artif Cells Nanomed Biotechnol. 2018;1–9. doi:10.1080/21691401.2018.1453827.
   Web of Science ®Google Scholar
• Fahlgren N, Howell MD, Kasschau KD, et al. High-throughput sequencing of arabidopsis microRNAs: evidence for frequent birth and death of miRNA genes. PLoS One. 2007;2:e219.
   PubMed Web of Science ®Google Scholar
• Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
   PubMed Web of Science ®Google Scholar
• Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:D149–D153.
   PubMed Web of Science ®Google Scholar
• Rehmsmeier M, Steffen P, Hochsmann M, et al. Fast and effective prediction of microRNA/target duplexes. RNA. 2004;10:1507–1517.
   PubMed Web of Science ®Google Scholar
• Romualdi C, Bortoluzzi S, d’Alessi F, et al. IDEG6: a web tool for detection of differentially expressed genes in multiple tag sampling experiments. Physiol Genomics. 2003;12:159–162.
   PubMed Web of Science ®Google Scholar
• Lupini L, Pepe F, Ferracin M, et al. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget. 2016;7:31361–31371.
   PubMedGoogle Scholar
• Bertero T, Gastaldi C, Bourget-Ponzio I, et al. CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ. 2013;20:800–811.
   PubMed Web of Science ®Google Scholar
• Peng L, Zhu H, Wang J, et al. MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. Mol Cell Biochem. 2015;405:73–79.
   PubMed Web of Science ®Google Scholar
• Fu H, Tie Y, Xu C, et al. Identification of human fetal liver miRNAs by a novel method. FEBS Lett. 2005;579:3849–3854.
   PubMed Web of Science ®Google Scholar
• Dai X, Pang W, Zhou Y, et al. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. J Diabetes. 2016;8:422–433.
   PubMed Web of Science ®Google Scholar
• Veronese A, Lupini L, Consiglio J, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 2010;70:3140–3149.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao LJ, Tan Y-X, et al. Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2012;18:5442–5453.
   PubMed Web of Science ®Google Scholar
• Yue J, Lv D, Wang C, et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Oncogene. 2018;37:4300–4312.
   PubMed Web of Science ®Google Scholar
• Valeri N, Braconi C, Gasparini P, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014;25:469–483.
   PubMed Web of Science ®Google Scholar